Samsung Biologics currently partners with more than 145 global pharmaceutical and biotechnology companies globally, as well as 17 of the world’s top 20 pharmaceutical companies, including AstraZeneca, Eli Lilly, and Pfizer.
Through these collaborations, Samsung Biologics helps develop and manufacture treatments addressing major global health challenges, including various types of cancer, COVID-19, autoimmune disorders, and inflammatory diseases, while supporting the next generation of biologic medicines through advanced research and technology.
Expanded manufacturing capacity at Rockville will deepen these partnerships.
State and Industry Leadership Mark the Milestone
On March 31, Samsung Biologics hosted an opening ceremony and ribbon-cutting event at the Rockville facility attended by local and state leaders, including Maryland Governor Wes Moore and Maryland Secretary of State Susan Lee. The event highlighted the company’s investment in Maryland’s biologics sector and the role the facility will play in supporting jobs, innovation, and biopharmaceutical manufacturing in the United States.
“This represents a meaningful step in expanding our U.S. manufacturing footprint. The addition of the Rockville site strengthens our ability to help produce lifesaving pharmaceuticals for patients across the globe, and we are thrilled to officially welcome more than 500 skilled American workers to the Samsung Biologics family,” said John Rim, President and CEO. “The Rockville team brings deep expertise and strong operational experience that will further strengthen the site as part of our global biomanufacturing network. As a CDMO, our mission is to bring important therapies and medicines to patients worldwide, and this site will play a pivotal role in that mission while strengthening our investment in the U.S.”
“Samsung Biologics’ investment in Montgomery County is a major win for Maryland and a clear example of how public investment and global partnerships help drive innovation, business and workforce opportunities and improve the health and well-being of our communities,” said Congresswoman April McClain Delaney. “As a member of the House Science, Space, and Technology Committee, I have seen how sustained federal support for research helps attract cutting-edge companies to our region. Located along the I-270 Technology Corridor, this new facility will benefit from Maryland’s uniquely collaborative innovation ecosystem—where federal labs, universities, and industry collaborate to drive progress. We’re proud to welcome Samsung Biologics to our science community and to celebrate their new facility.”
Looking Ahead
Samsung Biologics will continue supplying the products previously manufactured at the site to GSK under the terms of the agreement, and the site will transition to serve additional U.S. manufacturing needs. The team also plans to make additional investments to expand the site’s production capacity and upgrade technologies.
The completion follows the previously announced agreement to acquire the facility on December 22, 2025.
